NephroPlus reports strong FY26 results with revenue up 32.2% YoY to ₹998.8 Cr and adjusted EBITDA climbing 37.6% to ₹238.1 Cr, driven by increased treatments and international market growth.

Options to purchase securities

Agreements

Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

Analysts/Institutional Investor Meet/Con. Call Updates

Agreements

Shareholders meeting